Fragmentation in specialist care and stage III colon cancer

被引:44
作者
Hussain, Tanvir [1 ]
Chang, Hsien-Yen [2 ]
Veenstra, Christine M. [3 ]
Pollack, Craig Evan [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA
关键词
colon cancer; delivery of health care; health care costs; integrated health care systems; mortality; patient care management; HOSPITAL VOLUME; UNITED-STATES; HEALTH-CARE; SURGERY; RISK; PHYSICIANS; MORTALITY; DELIVERY; OUTCOMES; SOCIETY;
D O I
10.1002/cncr.29474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDPatients with cancer frequently transition between different types of specialists and across care settings. This study explored how frequently the surgical and medical oncology care of stage III colon cancer patients occurred across more than 1 hospital and whether this was associated with mortality and costs. METHODSThis was a retrospective Surveillance, Epidemiology, and End Results-Medicare cohort study of 9075 stage III colon cancer patients diagnosed between 2000 and 2009 who had received both surgical and medical oncology care within 1 year of their diagnosis. Patients were assigned to the hospital at which they had undergone their cancer surgery and to their oncologist's primary hospital, and then they were characterized according to whether these hospitals were the same or different. Outcomes included all-cause mortality, subhazards for colon cancer-specific mortality, and costs of care at 12 months. RESULTSThirty-seven percent of the patients received their surgical and medical oncology care from different hospitals. Rural patients were less likely than urban patients to receive medical oncology care from the same hospital (odds ratio, 0.62; 95% confidence interval, 0.43-0.90). Care from the same hospital was not associated with reduced all-cause or colon cancer-specific mortality but resulted in lower costs (8% of the median cost) at 12 months (dollars saved, $5493; 95% confidence interval, $1799-$9525). CONCLUSIONSThe delivery of surgical and medical oncology care at the same hospital was associated with lower costs; however, reforms seeking to improve outcomes and lower costs through the integration of complex care will need to address the significant proportion of patients receiving care at more than 1 hospital. Cancer 2015;121:3316-3324. (c) 2015 American Cancer Society. A significant proportion of colon cancer patients receive surgical and medical oncology care fragmented across more than 1 hospital. This fragmentation increases costs but may not affect survival.
引用
收藏
页码:3316 / 3324
页数:9
相关论文
共 50 条
  • [21] Nutritional risk screening score is associated with omission of adjuvant chemotherapy for stage III colon cancer
    Lee, Soo Young
    Yeom, Seung-Seop
    Kim, Chang Hyun
    Kim, Hyeong Rok
    [J]. AMERICAN JOURNAL OF SURGERY, 2020, 220 (04) : 993 - 998
  • [22] Adjuvant Chemotherapy for Stage III Colon Cancer: Does Timing Matter?
    Czaykowski, Piotr M.
    Gill, Sharlene
    Kennecke, Hagen F.
    Gordon, Vallerie L.
    Turner, Donna
    [J]. DISEASES OF THE COLON & RECTUM, 2011, 54 (09) : 1082 - 1089
  • [23] Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer
    Mayanagi, Shuhei
    Kashiwabara, Kosuke
    Honda, Michitaka
    Oba, Koji
    Aoyama, Toru
    Kanda, Mitsuro
    Maeda, Hiromichi
    Hamada, Chikuma
    Sadahiro, Sotaro
    Sakamoto, Junichi
    Saji, Shigetoyo
    Yoshikawa, Takaki
    [J]. DISEASES OF THE COLON & RECTUM, 2018, 61 (07) : 803 - 808
  • [24] Multi-institutional Care in Clinical Stage II and III Esophageal Cancer
    Rhodin, Kristen E.
    Raman, Vignesh
    Jensen, Christopher W.
    Kang, Lillian
    Nussbaum, Daniel P.
    Tong, Betty C.
    Blazer III, Dan G.
    D'Amico, Thomas A.
    [J]. ANNALS OF THORACIC SURGERY, 2023, 115 (02) : 370 - 377
  • [25] Comparison of laparoscopic complete mesocolic excision and traditional radical operation for colon cancer in the treatment of stage III colon cancer
    Yan, Dong
    Yang, Xiongfei
    Duan, Yaoxing
    Zhang, Weisheng
    Feng, Lili
    Wang, Tao
    Du, Binbin
    [J]. JOURNAL OF BUON, 2020, 25 (01): : 220 - 226
  • [26] Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer
    Sun, Zhifei
    Adam, Mohamed A.
    Kim, Jina
    Nussbaum, Daniel P.
    Benrashid, Ehsan
    Mantyh, Christopher R.
    Migaly, John
    [J]. DISEASES OF THE COLON & RECTUM, 2016, 59 (02) : 87 - 93
  • [27] Factors associated with delayed time to adjuvant chemotherapy in stage III colon cancer
    Chan, A.
    Woods, R.
    Kennecke, H.
    Gill, S.
    [J]. CURRENT ONCOLOGY, 2014, 21 (04) : 181 - 186
  • [28] Prognosis of Different Histological Types in Patients with Stage II and III Colon Cancer
    Qwaider, Yasmeen Z.
    Sell, Naomi M.
    Stafford, Caitlin E.
    Boudreau, Chloe
    Kunitake, Hiroko
    Goldstone, Robert N.
    Ricciardi, Rocco
    Bordeianou, Liliana G.
    Cauley, Christy E.
    Berger, David L.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (02) : 476 - 478
  • [29] Prognosis of Different Histological Types in Patients with Stage II and III Colon Cancer
    Yasmeen Z. Qwaider
    Naomi M. Sell
    Caitlin E. Stafford
    Chloe Boudreau
    Hiroko Kunitake
    Robert N. Goldstone
    Rocco Ricciardi
    Liliana G. Bordeianou
    Christy E. Cauley
    David L. Berger
    [J]. Journal of Gastrointestinal Surgery, 2022, 26 : 476 - 478
  • [30] Fragmentation of care in breast cancer: greater than the sum of its parts
    Freeman, Hadley D.
    Burke, Linnea C.
    Humphrey, Ja'Neil G.
    Wilbers, Ashley J.
    Vora, Halley
    Khorfan, Rhami
    Solomon, Naveenraj L.
    Namm, Jukes P.
    Ji, Liang
    Lum, Sharon S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (03) : 511 - 521